Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27,635 INR | +1.12% |
|
+2.95% | +20.93% |
11/06 | Abbott India Limited Announces Resignation of Sabina Ewing as Director, Effective June 12, 2024 | CI |
10/05 | Abbott India's Net Profit Climbs in Fiscal Q4; Shares Up 3% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 49.24 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+20.93% | 7.04B | B- | ||
+55.32% | 815B | C+ | ||
+44.05% | 641B | B | ||
-6.75% | 352B | C+ | ||
+13.56% | 314B | B- | ||
+10.68% | 303B | C+ | ||
+16.57% | 242B | B+ | ||
+2.04% | 224B | A+ | ||
+13.31% | 218B | B- | ||
+8.48% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
- Stock Market
- Equities
- ABBOTINDIA Stock
- Ratings Abbott India Limited